Rafferty Asset Management’s Cullinan Therapeutics CGEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$817K Sell
53,230
-12,862
-19% -$246K ﹤0.01% 809
2026
Q2
$1.2M Sell
66,092
-3,393
-5% -$50.4K ﹤0.01% 752
2026
Q1
$987K Buy
69,485
+7,814
+13% +$100K ﹤0.01% 777
2025
Q4
$638K Buy
61,671
+20,942
+51% +$189K ﹤0.01% 874
2025
Q3
$242K Buy
40,729
+1,503
+4% +$11K ﹤0.01% 1038
2025
Q2
$295K Sell
39,226
-15,716
-29% -$126K ﹤0.01% 984
2025
Q1
$416K Sell
54,942
-34,716
-39% -$333K ﹤0.01% 906
2024
Q4
$1.09M Sell
89,658
-25,012
-22% -$360K ﹤0.01% 774
2024
Q3
$1.92M Buy
114,670
+10,019
+10% +$178K 0.01% 646
2024
Q2
$1.83M Buy
104,651
+7,596
+8% +$162K 0.01% 672
2024
Q1
$1.65M Buy
+97,055
New +$1.5M 0.01% 733
2022
Q2
– Sell
-55,152
Closed -$577K – 1151
2022
Q1
$577K Sell
55,152
-15,987
-22% -$216K ﹤0.01% 928
2021
Q4
$1.1M Buy
+71,139
New +$1.42M 0.01% 827

Other funds holding CGEM

Rafferty Asset Management's CGEM Position: Q3 2026 in Review

Rafferty Asset Management reduced its Cullinan Therapeutics (CGEM) stake by 19% in Q3 2026, selling an estimated $246K and leaving 53,230 shares worth $817K. The position accounts for ﹤0.01% of the portfolio, ranked #809.

Rafferty Asset Management first reported a position in CGEM in Q4 2021 and has held it in 13 quarters since. The position peaked at $1.92M in Q3 2024. 182 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.

  • Rafferty Asset Management held 53,230 shares of Cullinan Therapeutics worth $817K as of Q3 2026.
  • Rafferty Asset Management sold 12,862 Cullinan Therapeutics shares in Q3 2026, an estimated $246K.
  • Cullinan Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q3 2026, its #809 holding.
  • Rafferty Asset Management first reported a position in Cullinan Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • Rafferty Asset Management's Cullinan Therapeutics position peaked at $1.92M in Q3 2024.
  • 182 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.

Based on Rafferty Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.